Biotech horsekeepers

Credit: © SHARON MORRIS" /> Credit: © SHARON MORRIS In the 1940s Jules Freund, inventor of Freund's adjuvant, worked on developing antibodies in horse to rabbit serum globulin. In a 1947 Journal of Experimental Medicine study, Freund describes the horses by number: 1026, 999, 1127. To others, they had names like Sylvester, Moses, and Doc Fried. The horses had retired from the New York City police department to reside at stables on a 170-acre plot of land in the tiny tow

Written byKerry Grens
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

In the 1940s Jules Freund, inventor of Freund's adjuvant, worked on developing antibodies in horse to rabbit serum globulin. In a 1947 Journal of Experimental Medicine study, Freund describes the horses by number: 1026, 999, 1127. To others, they had names like Sylvester, Moses, and Doc Fried.

The horses had retired from the New York City police department to reside at stables on a 170-acre plot of land in the tiny town of Otisville, NY, 80 miles from midtown Manhattan in the shadow of the Catskill Mountains. New York City has been sending horses to Otisville since 1906. On this same land is the 10,000-square foot Otisville Complex. The New York City Department of Health originally owned it as a municipal sanitarium for tuberculosis, and the complex and land were home in the first decades of the 20th century to research that developed antitoxin to diphtheria. Horse serum produced the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies